Cannabinoid receptors and endocannabinoids: Evidence for new players

AAPS Journal

Volumn 8, Issue 2, 2006, Pages

  Mackie, Ken ^a   Stella, Nephi ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoids; Drug of abuse; Marijuana; Receptor

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOL; CANNABIS; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; METHANANDAMIDE; PALMIDROL; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL; CANNABIS ADDICTION; CARDIOVASCULAR SYSTEM; DRUG RECEPTOR BINDING; HUMAN; HYPOTENSION; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MOLECULAR DYNAMICS; NEUROMODULATION; NONHUMAN; PROTEIN LOCALIZATION; REVIEW; SYNAPTIC TRANSMISSION; VASODILATATION;

ANIMALS; BRAIN; ENDOCANNABINOIDS; HUMANS; NEURONS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID;

EID: 33646814424     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080234     Document Type: Review

References (119)

1. Watson SJ, Benson JA, Joy JE. Marijuana and medicine: assessing the science base. Arch Gen Psychiatry. 2000;57:547-552.
2. Iversen LL. The Science of Marijuana. Oxford, UK: Oxford University Press; 2000.
3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647.
4. Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352:1611-1616.
5. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000;97:9561-9566.
6. Herring AC, Kaminski NE. Cannabinol-mediated inhibition of nuclear factor-κB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther. 1999;291:1156-1163.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
9. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83:1017-1066.
10. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84-88.
11. Rodríguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci. 2001;21:823-833.
12. Molina-Holgado E, Vela JM, Arévalo-Martin A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptor and phosphatidyllinositol-3 kinase/Akt signaling. J Neurosci. 2002;22:9742-9753.
13. Aguado T, Monory K, Palazuelos J, et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J. 2005;19:1704-1706.
14. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing the cannabinoid receptor clones. Mol Pharmacol. 1992;42:838-845.
15. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci. 1997;17:5327-5333.
16. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001;58:322-328.
17. Straiker A, Mackie K. Depolarization-induced suppression of excitation in routine autaptic hippocampal neurones. J Physiol. 2005;569:501-517.
18. Kelley BG, Thayer SA. Delta 9-tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology. 2004;46:709-715.
19. Jordan JD, He JC, Eungdamrong NJ, et al. Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/ i-triggered proteasomal degradation of Rap1 GAPII. J Biol Chem. 2005;280:11413-11421.
20. Kim D, Thayer SA. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci. 2001;21:RC146.
21. Jin K, Xie L, Kim SH, et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol. 2004;66:204-208.
22. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54-61.
23. Patrini G, Sacerdote P, Fuzio D, Manfredi B, Parolaro D. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound. J Neuroimmunol. 1997;80:143-148.
24. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 1998;75:111-119.
25. 9-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol. 2000;387:343-347.
26. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396:141-149.
27. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48:443-450.
28. Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228-14233.
29. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002;135:181-187.
30. 9-tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther. 1995;273:1216-1223.
31. McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther. 1999;289:1620-1625.
32. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther. 2002;302:451-465.
33. Derocq J-M, Ségui M, Marchand J, Le Fur G, Casellas P. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett. 1995;369:177-182.
34. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142:278-287.
35. Sugiura T, Kondo S, Kishimoto S, et al. Evidence that 2-arachidonylglycerol but not N-palmitpylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor: comparison of the agonistic activities of various cannabinoid receptor ligands in BL-60 cells. J Biol Chem. 2000;275:605-612.
36. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol. 2002;2:69-82.
37. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329-332.
38. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005;95:437-445.
39. Benito C, Nũnez; E, Tolón RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaques-associated glia in Alzheimer's disease brains. J Neurosci. 2003;23:11136-11141.
40. Walter L, Franklin A, Witting A, et al. Non-psychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003;23:1398-1405.
41. Kishimoto S, Gokoh M, Oka S, et al. 2-Arachidonoylglycerol induces the migration of BL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem. 2003;278:24469-24475.
42. Jordà MA, Verbakel SE, Valk PJ, et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocarmabinoid 2-arachidonoylglycerol. Blood. 2002;99:2786-2793.
43. Gokoh M, Kishimoto S, Oka S, et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochem J. 2005;386:583-589.
44. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther. 1999;288:1357-1366.
45. Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol. 2003;139:775-786.
46. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia. 2003;41:161-168.
47. Carrier EJ, Kearn CS, Barkmeier AJ, et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004;65:999-1007.
48. Derocq J-M, Jbilo O, Bouaboula M, Ségui M, Clère C, Casellas P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60: possible involvement of the CB2 receptor in cell differentiation. J Biol Chem. 2000;275:15621-15628.
49. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
50. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686-691.
51. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999;2:358-363.
52. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA. 1999;96:12198-12203.
53. Di Marzo V, De Petrocellis L, Sugiura T, Waku K. Potential biosynthetic connections between the 2 cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem Biophys Res Commun. 1996;227:281-288.
54. Cadas H, Schinelli S, Piomelli D. Membrane localization of N-acylphosphatidylethanolamine in central neurons: studies with exogenous phospholipases. J Lipid Mediat Cell Signal. 1996;14:63-70.
55. Sugiura T, Kondo S, Sukagawa A, et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes: comparison with synthesis from free arachidonic acid and elitanolamine Eur J Biochem. 1996;240:53-62.
56. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279:5298-5305.
57. Piomelli D. The challenge of brain lipidomics. Prostaglandins Other Lipid Mediat. 2005;77:23-34.
58. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids: Nature. 1998;394:277-281.
59. Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 1996;393:231-235.
60. Schmid PC, Kuwae T, Krebsbach RJ, Schmid HHO. Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. Chem Phys Lipids. 1997;87:103-110.
61. Schmid PC, Paria BC, Krebsbach RJ, Schmid HHO, Dey SK. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA. 1997;94:4188-4192.
62. Calignano A, Kátona I, Désarnaud F, et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature. 2000;408:96-101.
63. Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 1993;44:498-503.
64. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol. 1993;231:313-314.
65. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001;98:9371-9376.
66. Griffin G, Tao Q, Abood ME. Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. J Pharmacol Exp Ther. 2000;292:886-894.
67. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 2000;57:1045-1050.
68. Kathuria. S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9:76-81.
69. Hampson AJ, Hill WAG, Zan-Phillips M, et al. Anandamide hydroxylation by brain lipoxygenase: metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta. 1995;1259:173-179.
70. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 1997;272:21181-21186.
71. Weber A, Ni J, Ling KH, et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res. 2004;45:757-763.
72. Kim J, Alger BE. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci. 2004;7:697-698.
73. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
74. Sugiura T, Kondo S, Sukagawa A, et al. 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89-97.
75. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388:773-778.
76. Prescott SM, Majerus PW. Characterization of 1,2-diacylglycerol hydrolysis in human platelets: demonstration of an arachidonoylmonoacylglycerol intermediate. J Biol Chem. 1983;258:764-769.
77. Farooqui AA, Taylor AW, Horrocks LA. Separation of bovine brain mono- and diacylglycerol lipases by heparin sepharose affinity chromatography. Biochem Biophys Res Commun. 1984;122:1241-1246.
78. Maejima T, Oka S, Hashimotodani Y, et al. Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J Neurosci. 2005;25:6826-6835.
79. Hashimotodani Y, Ohno-Shosaku T, Tsubokawa H, et al. Phospholipase Cbeta serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal. Neuron. 2005;45:257-268.
80. Bisogno T, Howell F, Williams G, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463-468.
81. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J. 1997;322:671-677.
82. Bisogno T, Maccarrone M, De Petrocellis L, et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem. 2001;268:1982-1989.
83. Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport. 2000;11:1231-1235.
84. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA. 2002;99:10819-10824.
85. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol. 2004;66:1260-1264.
86. Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem. 2000;275:33744-33749.
87. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 1998;422:69-73.
88. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001;60:155-163.
89. Di Marzo V, Breivogel CS, Tao Q, et al. Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J Neurochem. 2000;75:2434-2444.
90. Hájos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 2001;106:14.
91. Hájos N, Freund TF. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology. 2002;43:503-510.
92. Hoffman AF, Macgill AM, Smith D, Oz M, Lupica CR. Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur J Neurosci. 2005;22:2387-2391.
93. Rouach N, Nicoll RA. Endocannabinoids contribute to short-term but not long-term mGluR-induced depression in the hippocampus. Eur J Neurosci. 2003;18:1017-1020.
94. Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology. 2004;46:115-125.
95. Houser SJ, Eads M, Embrey JP, Welch SP. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res. 2000;857:337-342.
96. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther. 1998;286:1301-1308.
97. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005;106:133-145.
98. Járai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 1999;96:14136-14141.
99. Offertáler L, Mo F, Bátkai S, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol. 2003;63:699-705.
100. Begg M, Mo F-M, Offertáler L, et al. G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem. 2003;278:46188-46194.
101. Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993;214:173-180.
102. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74:486-496.
103. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004;141:775-785.
104. Lambert DM, Vandevoorde S, Jonsson K-O, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem. 2002;9:663-674.
105. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998;76:189-199.
106. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci. 1997;17:1226-1242.
107. Hansen HS, Lauritzen L, Strand AM, Vinggaard AM, Frandsen A, Schousboe A. Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J Neurochem. 1997;69:753-761.
108. Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol. 2001;425:189-196.
109. Walter L, Franklin A, Witting A, Möller T, Stella N. Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem. 2002;277:20869-20876.
110. Walter L, Stella L. Endothelin-1 increases 2-arachidonyl glycerol (2-AG) production in astrocytes. Glia. 2003;44:85-90.
111. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cells motility. J Neurosci. 2003;23:7767-7775.
112. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem. 2001;276:35552-35557.
113. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem. 2005;280:11082-11092.
114. Ueda N, Tsuboi K, Lambert DM. A second N-acylethanolamine hydrolase in mammalian tissues. Neuropharmacology. 2005;48:1079-1085.
115. Sun YX, Tsuboi K, Zhao LY, Okamoto Y, Lambert DM, Ueda N. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta. 2005;1736:211-220.
116. Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of 2 endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20:441-458.
117. Sawzdargo M, Nguyen T, Lee DK, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999;64:193-198.
118. Brown A, Wise A, inventors. GlaxoSmithKline, assignee. Identification of modulators of GPR55 activity. US patent 0 113 814. June 19, 2003.
119. Drmota T, Greasley P, Groblewski T, inventors. AstraZeneca, assignee. Screening assays for cannabinoid-ligand-type modulators of GPR55. WIPO patent 074 844. September 2, 2004.